Autonomix Medical Awarded U.S. Patent Covering Cancerous Tumors Treatment and Cancer Related Pain with Company’s Catheter-Based Technology

December 30, 2024

DENVER, Colo., Dec 30, 2024 (247marketnews.com)- Autonomix Medical (NASDAQ: AMIX) stated that the United States Patent and Trademark Office (USPTO) issued U.S. patent 12,064,256 (‘256 patent) titled, Systems and Methods for Treating Cancer and/or Augmenting Organ Function, to the Company, covering technology including, but not limited to, systems, methods and devices for interventionally treating cancerous tumors and cancer related pain, which Autonomix is initially advancing the development of its technology to address pancreatic cancer-related pain.

Brad Hauser, CEO of Autonomix, commented, “As we continue to advance the development of this potentially groundbreaking technology, bolstering our patent protection remains a key priority.

“Supported by recent positive preclinical results demonstrated to date, we believe the depth and breadth of our proprietary technology provides the opportunity for further evaluation and we intend to explore its potential to reduce cancer progression and metastases.”

Autonomix’s catheter-based sensing technology is covered by over 80 issued patents and over 40 pending patent applications, globally.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (AMIX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.